The BAMI project addresses the specific aims and objectives of the EU-FP7 Call: Health.2011.1.4-1: Regenerative medicine clinical trials.

As clinical data now exists supporting the concept that autologous bone marrow derived cells can restore cardiac function following acute myocardial infarction (AMI).

The objective is to advance this research in the BAMI project and will develop a standardised method of bone marrow cell collection, develop a standardised method of optimising reparative potential of bone marrow derived cells, standardise bone marrow preparation procedure so that it can be universally applied, standardise method of bone marrow cell delivery post AMI and conduct the first large scale all-cause mortality clinical trial to test if the product and delivery method mentioned above can lead to a 25% reduction in mortality.

The BAMI project will establish the therapeutic value of this approach to stem cell therapy.

Success will demonstrate that trans-coronary infusion of bone marrow-derived progenitor cells is safe and will reduce the mortality rate by 25% and reduce the re-hospitalisation rate by 15%.



The BAMI project has been partially funded by the European Commission

Seventh Framework Programme (FP7)

To find out more click on the links below

Seventh Framework Programme FP7 Cooperation E.U. Health E.U. Clinical Trials